Skip to main content
Keith Pratz, MD, Oncology, Philadelphia, PA, Hospital of the University of Pennsylvania

KeithWilliamPratzMD

Oncology • Philadelphia, PA

Associate Professor of Medicine, Director of Leukemia, University of Pennsylvania

Join to view full profile

Dr. Pratz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Pratz's full profile

Already have an account?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
  • Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical SchoolClass of 2002

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 2019 - 2024
  • MD State Medical License
    MD State Medical License 2006 - 2019
  • MN State Medical License
    MN State Medical License 2003 - 2007
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia  
    Courtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
  • Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
    Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood

Abstracts/Posters

  • Coagulopathy, Hypoxemia, and Mortality Outcomes in Newly Diagnosed Acute Myeloid Leukemia with Hyperleukocytosis Treated with Large Volume Leukapheresis
    Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
    Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    Keith W. Pratz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • New Therapies for Better Patient Outcomes in Acute Myeloid Leukemia: Integration of Recent Data Sets Into Clinical Practice 
    60th American Society of Hematology Annual Meeting - 11/30/2018

Authored Content

  • Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
  • Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
  • Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
  • Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
  • Join now to see all

Press Mentions

  • Keith W. Pratz, MD, on the Prognostic Value of MRD in AML Low-Intensity Treatment
    Keith W. Pratz, MD, on the Prognostic Value of MRD in AML Low-Intensity TreatmentJune 3rd, 2022

Hospital Affiliations

External Links

Dr. Keith Pratz, Dr. Keith Pratz, MD, Dr. K Pratz, Dr. Keith William Pratz